Sandbox Reserved 1133

From Proteopedia

proteopedia linkproteopedia link

Revision as of 13:11, 15 December 2015 (edit) OCA (Talk | contribs) (New page: {{Sandbox_Reserved_ESBS_2015}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE --> ==Your Heading Here (maybe something like 'Structure')== <StructureSection load='1stp' size='340' side='right' cap...) ← Previous diff		Revision as of 21:19, 26 January 2016 (edit) (undo) Tiphaine Wong (Talk | contribs) (Début de rédaction) Next diff →
Line 1:		Line 1:
-	{{Sandbox_Reserved_ESBS_2015}}<!-- PLEASE ADD YOUR CONTENT BELOW HERE -->	+	== General presentation of the protein: ==
-	==Your Heading Here (maybe something like 'Structure')==	+
-	<StructureSection load='1stp' size='340' side='right' caption='Caption for this structure' scene=''>	+	The PD-1 protein, also known as CD279, is a program cell-death 1 protein which plays a particular role in the activation of T-lymphocytes. This cell surface receptor is located on pro-B cells and T cells and belongs to the immunoglobulin super family. It can bind two ligands: PD-L1 and PD-L2.
-	This is a default text for your page ''''''. Click above on '''edit this page''' to modify. Be careful with the &lt; and &gt; signs.	+	Even if it structure is not yet totally characterized, PD-1 seems to be a promising target in therapy and has begun to be used as tumor repressor.
-	You may include any references to papers as in: the use of JSmol in Proteopedia <ref>DOI 10.1002/ijch.201300024</ref> or to the article describing Jmol <ref>PMID:21638687</ref> to the rescue.	+
-	== Function ==	+	== History : ==
		+
		+	PD-1 cDNA was discovered in 1992 by Ishida et Al. The discovery of the role of PD-1 in deficiency and autoimmunity was discovered during the studies on PD-1-deficient mice on the C57BL/6 background.
-	== Disease ==	+	== Clinical applications: ==
-		+
-	== Relevance ==	+	PD-1 negatively regulates immune response and is used for immunotherapy and particularly for cancers.
-		+	Nivolumab (Opdivo, Bristol-Myers Squibb), an antibody-drug, was then developed to block the activity of this receptor and is given to treat metastatic melanomas. This drug prevents the binding of the PD-1 ligands; PD-L1 a inhibitor of PD-1; which permits T-cells to work.
-	== Structural highlights ==	+	For the same applications, Pembrolizumab (Keytruda, MK-3475, Merck)) has been developed and is used since March 2015 in the UK for advanced melanoma and it is in the clinical trials in the US.
-		+	Others drugs are being developed such as Pidilizumab (CT-011, Cure Tech), BMS 936559 (Bristol Myers Squibb), and MPDL328OA (Roche).
-	This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.	+
-		+
-	</StructureSection>	+
-	== References ==	+
-	<references/>	+

---

Revision as of 21:19, 26 January 2016

General presentation of the protein:

The PD-1 protein, also known as CD279, is a program cell-death 1 protein which plays a particular role in the activation of T-lymphocytes. This cell surface receptor is located on pro-B cells and T cells and belongs to the immunoglobulin super family. It can bind two ligands: PD-L1 and PD-L2. Even if it structure is not yet totally characterized, PD-1 seems to be a promising target in therapy and has begun to be used as tumor repressor.

History :

PD-1 cDNA was discovered in 1992 by Ishida et Al. The discovery of the role of PD-1 in deficiency and autoimmunity was discovered during the studies on PD-1-deficient mice on the C57BL/6 background.

Clinical applications:

PD-1 negatively regulates immune response and is used for immunotherapy and particularly for cancers. Nivolumab (Opdivo, Bristol-Myers Squibb), an antibody-drug, was then developed to block the activity of this receptor and is given to treat metastatic melanomas. This drug prevents the binding of the PD-1 ligands; PD-L1 a inhibitor of PD-1; which permits T-cells to work. For the same applications, Pembrolizumab (Keytruda, MK-3475, Merck)) has been developed and is used since March 2015 in the UK for advanced melanoma and it is in the clinical trials in the US. Others drugs are being developed such as Pidilizumab (CT-011, Cure Tech), BMS 936559 (Bristol Myers Squibb), and MPDL328OA (Roche).